The term is used by some women to describe symptoms after stopping hormonal contraception, but medical research has not established it as a distinct condition caused by a hormonal imbalance.
Mirena is a hormonal intrauterine device (IUD) that releases levonorgestrel, a synthetic hormone used to prevent pregnancy. Some women report changes in mood, headaches, bleeding patterns and other symptoms after its removal, but there is insufficient evidence to conclude that these experiences form a distinct medical condition known as “Mirena crash”.
The term has gained attention through personal accounts shared online. However, those reports do not establish that removing Mirena causes a deficiency of natural progesterone or that a specific set of symptoms will follow.
Medical assessment is important when symptoms develop after removal because several conditions, including changes in the menstrual cycle and unrelated health problems, can produce similar effects.
Mirena’s uses and possible side effects
Mirena is a T-shaped device placed inside the uterus by a trained healthcare professional. According to the US National Library of Medicine’s DailyMed drug information, it is approved in the United States to prevent pregnancy for up to eight years and to treat heavy menstrual bleeding for up to five years in women using it for contraception.
The device releases levonorgestrel, a progestin that acts mainly within the uterus. It thickens cervical mucus, making it more difficult for sperm to reach an egg, and thins the uterine lining. It does not work by supplying natural progesterone or by treating infertility.
Documented side effects include changes in menstrual bleeding, pelvic or abdominal pain, headaches and, in some users, ovarian cysts. Hormonal IUDs can also be associated with mood changes and breast tenderness. The presence of these symptoms does not, by itself, establish that a woman is experiencing a post-removal hormonal disorder.
What happens after removal?
Mirena removal ends the device’s ongoing release of levonorgestrel. Menstrual patterns and other symptoms may change as the body returns to its usual cycle, but the claim that removal routinely causes a hormonal imbalance lasting several months has not been established.
The manufacturer’s prescribing information reports that approximately 80 percent of women who wanted to become pregnant after discontinuing Mirena conceived within 12 months in two studies. This indicates that fertility can return after removal, although individual outcomes vary.
Women who develop persistent mood changes, unusual bleeding, pelvic pain or other symptoms after removal should consult a qualified healthcare professional. A clinician can assess the symptoms and determine whether they are related to menstrual changes or another condition.
Severe abdominal pain, particularly when accompanied by fainting or unusual bleeding, requires urgent medical assessment. If pregnancy occurs while an IUD is in place, an ectopic pregnancy, in which a fertilised egg implants outside the uterus, must be considered. Although IUDs greatly reduce the overall risk of pregnancy, a pregnancy that occurs with one in place is more likely to be ectopic.
Breast cancer and other safety concerns
Research has examined whether hormonal contraception, including levonorgestrel-releasing IUDs, is associated with breast cancer. The American College of Obstetricians and Gynecologists reported in a 2018 practice advisory that one large Danish study found a small increase in relative breast cancer risk among users of hormonal contraception, including users of levonorgestrel-releasing IUDs. The findings do not establish that Mirena causes breast cancer in an individual user, and the absolute risk for younger women remains low.
The US prescribing information lists known or suspected breast cancer among the conditions in which Mirena should not be used. Women concerned about their personal risk should discuss their medical history and contraceptive options with a healthcare professional.
Claims linking Mirena to pseudotumor cerebri, also known as idiopathic intracranial hypertension, have also been examined in US courts. In December 2020, the US Court of Appeals for the Second Circuit upheld a decision in litigation involving claims that Mirena caused the condition. The court record concerned whether the plaintiffs had provided sufficient admissible expert evidence to support their claims. The litigation outcome should not be confused with proof that every reported symptom is unrelated to the device.
The claims also refers to copper toxicity, but copper IUDs are different from Mirena, which contains no copper. The two devices should not be treated as interchangeable when discussing their mechanisms or possible complications.
The available evidence does not establish “Mirena crash” as a distinct diagnosis or confirm that the symptoms attributed to it result from a progesterone deficiency. Women experiencing symptoms after removal should receive an individual medical assessment rather than assume that a hormonal imbalance is the cause.
